mercredi 31 octobre 2018

Onco Actu du 31 octobre 2018

1. Biologie

Patient-derived Paediatric Brain Tumour Models [ESMO]

4.2 Dép., diag. & prono. - Génome

Long read technologies – the next frontier of clinical genome sequencing? [PHG Foundation]

4.3 Dép., diag. & prono. - Industriels

Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling [Illumina]

5.10 Traitements - Essais

Research integrity: clinical trials transparency [House of Commons Science and Technology Committee]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

New Penn Medicine Center Brings Immunotherapy Research to Brain Tumor Treatment [Penn Medicine]

City Of Hope Opens First-Of-Its-Kind Car T Clinical Trial For Patients With Her2-Positive Breast Cancer That Has Spread To The Brain [City of Hope]

5.12.6 Immunothérapies - AMM

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) [Merck]

5.2 Pharma

Sanofi joins Open Targets [Open Targets]

5.2.1 Pharma - Partenariats

Roche taps Halozyme’s drug delivery tech for up to $520M [FierceBiotech]

6. Lutte contre les cancers

Report Outlines Priorities to Improve the Lives of Cancer Survivors and Caregivers (ACS]

6.1 Observation

Half of kidney cancer patients initially misdiagnosed [Pharmafile]

Patient Survey Results Autumn 2018 [Kidney Cancer UK]

6.12 Ethique

Wellcome Sanger director apologises for management failings [The Guardian]

Result of independent investigation into whistleblowing allegations released [Wellcome Sanger Institute]

Top genomics institute clears director of bullying and gender discrimination [Nature]

6.5 Médecines alternatives/complémentaires

National Survey Reveals Surprising Number of Americans Believe Alternative Therapies Can Cure Cancer [ASCO]

6.7.1 IA/bioinformatique

Google Touts Speed, Accuracy From Machine Learning in DeepVariant [Genome Web]

Why Jupyter is data scientists’ computational notebook of choice [Nature]